Mckinsaey paperDec在数字时代制药企业如何生存 How pharma can win in a digital world.docx
《Mckinsaey paperDec在数字时代制药企业如何生存 How pharma can win in a digital world.docx》由会员分享,可在线阅读,更多相关《Mckinsaey paperDec在数字时代制药企业如何生存 How pharma can win in a digital world.docx(11页珍藏版)》请在冰豆网上搜索。
MckinsaeypaperDec在数字时代制药企业如何生存Howpharmacanwininadigitalworld
Howpharmacanwininadigitalworld
ByDavidChampagne,AmyHung,andOlivierLeclerc
ArticleDecember2015
Thedigitalrevolutioniswellunderwayforpharmacompanies.Wespokewith20leadingexecutivesto findouthowtheycope—andwhattheydotostayahead.
Thedigitalrevolution continuestotransformhealthcarefundamentally,andmanypeoplebelievethatatippingpointisfinallywithinreach.In2014,digitalhealthinvestmentstopped$6.5billion,comparedwith$2.9billionayearearlier.1
Thecriticalquestionnowforpharmaceuticalcompaniesishowtostayaheadofthesechanges.Toanswerit,wesoughttolearnthetrendsandimplicationsofdigitalhealthbyinterviewing20thoughtleadersacrossavarietyofsegments,includinganalytics,biotech,data,pharma,providers,technology,andventurecapital.Theconsensusisthatashealthcarecontinuestodigitize,pharmacompaniesmusttransformthemselvesinbasicwaystostaycompetitive.Successfuloneswillrethinktheirbusinessandoperatingmodels,transformtheirculturesandcapabilities,andadoptanew,longer-termmind-setthatfostersinnovationandboldstrategicmoves.2Theseconclusionsstemfromthreeimportantthemesthatwetookawayfromourconversations:
1.Dramaticchangesinthetraditionalrolesanddynamicsofhealthcarestakeholdershavefundamentalimplicationsforpharmacompanies.
2.Itistimetoreimaginethemassolutionscompanies,notassetcompanies.
3.Thetechnologyisready,butpharmacompaniesmustchangeiftheyaregoingtoenableandharnessitmoresuccessfully.
Thesethemesstronglysuggestthatsuccessinthenewdigitalenvironmentwillrequirethreebigshifts:
forgingaheadbeyondthepackmentalityandembracingexperimentationandrisktaking,developingacollaborativecultureandchallengingbarrierstosharing,andreinventingcompaniesbybuildingcapabilitiesbeyondtraditionalhealthcareandupdatingtheoperatingmodel.
Emergingthemes
Dramaticchangesinthetraditionalrolesanddynamicsofhealthcarestakeholdershavebasicimplicationsforpharmacompanies.Thedigitalrevolutionhasspawnedaconsumerrevolutionsymbolizedbyanincreasingdemandforconnectednessandinformation.Consumerswithnewtechnologytoolsarebecomingmoreactiveandself-directive,whichchangestheirinteractionswithproviders,payors,andpharmacompanies.Asaresult,newandunfamiliarformsofbehaviorwillfundamentallyaffectthepharmaceuticalbusiness:
∙Individualsarestartingtocontroltheirownhealthtreatments.Patientsarebecomingmorethanjustpassiverecipientsoftherapies.“Healthcarewillbedrivenmuchmorebyconsumersthanphysicians,withpatientsincreasinglycomingtotheirdoctorswithmoreinformation,parameterstheymeasuredathome,andaninformedopinionabouthowtheyshouldbetreated,”saysDr.BertalanMesko,medicalfuturistandauthorof MyHealth:
Upgraded (Webicina,September2015)and TheGuidetotheFutureofMedicine (Webicina,2014).DanGoldsmith,thechiefstrategyofficerofVeevaSystems,acloud-basedlife-sciencebusiness-solutionscompany,takestheideafurther.“Inthenext3-5years,”Goldsmithsays,“insteadofpatientsjustbeinginformedandmoreinquisitive,theywillbeactivelydesigningthetherapeuticandtreatmentapproachesforthemselveswiththeirphysicians.”
Aspatientsassumegreatercontrolovertheirownhealth,includingthetherapeuticstheytake,pharmacompaniesmustrecognizethisnewdecision-makingpoweranddevelopbetterwaystoengagethem.That’snoteasy.LiMa,vicepresidentofstrategyandinvestmentatAlibabaHealthInformationTechnology,saysthat“manypharmacosaretryingtoengagepatients.Butitisdifficultbecausetheyoftendon’tknowexactlywhotheirpatientsareandalsohaveahardtimedeterminingexactlywhatengagementmodelresonateswiththeirpatients.”
Somepharmacompaniesalreadyrecognizethegrowingimportanceofconnectingwithpatientsandaredoingsomethingaboutit.Asthecustomer-experiencedirectoratonetoppharmacompanysays,“Weusedifferentapproaches,dependingonthetargetaudience,toreachpatientsacrossanumberofchannelsthatrelatespecificallytotheirpreferences.Weobservepatientbehaviorviaonlinecommunities,participateindialoguesonresearchcommunities,havein-homevisits,observepatient–physicianinteractions,andusequantitativemethodstoanalyzetrendsandadjustcontentasneededtodrivebetterengagement.”
Ifpharmacompanieswanttogobeyondengagementandtrulyencouragechangesinhealthbehavior,theywillneedtocreatedifferentkindsofsolutions.Althoughmanysolutions,particularlyapps,havebeendevelopedinthepastfewyears,notallcanbeadopted.AsDr.ToddJohnson,theCEOofNoble.MD,putsit:
“Appsthatfacethepatientbutaredesignedtosolvepharma-companybusinessneedsshouldneverexist.Conversely,themarketdesperatelyneedsappsthatfocusonpatientand/orproviderneeds—realneedswithameasurableimpactonhealthqualityandcost.Ifthoseappsalsomeetbusinessneeds—asasecondaryortertiaryoutcome—theyhaveachanceofbeingadopted.”
∙Theclinicalenvironmentwillchangefundamentally. Asconsumersbecomemoreengagedandcareenvironmentsmorecomplex,physicianswillneednewskillsandtools.“Howdoctorsspendtheirtimewillchangedramatically,”saysVinodKhosla,foundingCEOofSunMicrosystemsandfounderofKhoslaVentures.“Theywillshifttospendingasmallerproportionofitorderingdiagnosticsandinterpretingresults,andmuchmoreonthesocialelementsofhealthcare—helpingpatientsandfamiliesthinkthroughtreatmentoptions.”
Physicianswillalsohavetointegrateincreasinglymassivequantitiesoftraditionalandnontraditionalhealthdata—forexample,hundredsoffragmentedelectronichealthrecords,aswellasdatafromthousandsofwearabledevicesandother“quantifiedself”technologies.Thisadvanceiscrucialbecause“wearabledevicesthattodayarestillinthemorerecreational-gradestatearechangingincrediblyrapidlyintoresearch-gradeand,ultimately,clinical-grade”tools,notesDr.EricSchadt,foundingdirectorofIcahnInstituteatMountSinai.
Inthenearfuture,physiciansmayreceiveaconstant,dailystreamofdatafromsomepatients.TheDiovanhypertensionpill,withtheembeddedProteuschip,isalreadyintrials,withstellarpatient-complianceresults.3Thechiprecordsthetimewhenthepatienttakesapillandtransmitsthisinformationfrominsidethebodytoapatchthepatientwears.(Thepatchalsocapturesotherphysiologicaldata.)Thisinformationcanbesharedwithasmartphone,alaptop,andthecloud,sothepatientandprovidercanaccessit.SuchdevelopmentshavepromptedDr.KrishnaYeshwant,generalpartneratGoogleVentures,toconcludethat“physiciansneedtooperateinamorecomplexenvironmentwithanever-growingrangeoftools.Physiciansneedapackageofsolutionstonavigatethisenvironment.”
∙Patients’brandloyaltydwindlesascostconsciousnessrises. Peoplearenowmuchlessloyaltobrandsandcompanies—boththeirinsurancecompaniesandthepharmacompaniesthatmaketheirmedicines.“Theaveragetenureforamembertobeonanindividualinsuranceplanisnowsomethingliketwotothreeyears,”saysSanjayMathur,CEOofSiliconValleyDataScience.Thereasonsvary,frommorefrequentjobswitchingtoemployersthatadoptnewplanstocutcosts,henotes.“Inthefuture,noonewillcarewhatbrandofdrugtheywilltake.Andwithdevice,behavior,andhealth-proxydataavailable,theirmethodofselectingdrugswillchangedramatically.”Theincreasedcostconsciousnessofpatientsexacerbatesthistendency:
theycomparewhattheywouldpayfordifferentplansandtheefficacyandpricepointsofdifferenttreatments.
∙Pharmacompanieswillloseexclusivecontrolovertheirvaluestories.Asthelinesamongpayors,providers,andpharmacompaniesblur,carefullycontrolledtrialdatawillnolongerbethesolesourceofoutcomedata.Thedynamicsbetweenplayersareevolving:
payorsareexpandingintoareasthatprovidersandpharmacompaniestraditionallyowned(forexample,payorsareinsomecasesexcludingdrugscompletelyfromtheirformularies).“Withhealthdatabecomingmorereadilyavailableinamoredigestibleform,payorsandprovidersalikewillhavemoreinformationtolinkdrugstooutcomesandinformvalue-basedpricing,”saysAmyAbernethy,MDandPhD,thechiefmedicalofficerandseniorvicepresidentofoncologyatFlatironHealth.“Thehealthcareindustrywillstarttomerge,andthelinesacrossstakeholderswillblurveryquickly,”addsDr.WolfgangLippertofS’sHealthcareandLifeSciencesIndustryBusinessUnit.“Payorswillbecomeincreasinglylikeprovidersinofferinginterventionsandhomecare,andincreasinglylikepharmainanalyzingdataandpressure-testingvalue,”hepredicts.
Forpharmacompanies,itwillnotbeenoughtoacceptthattheywon’tcontinuetofullycontroltheirproductdata.Toaccessreal-worlddatafrommanysources,theywillalsoneedtoprovideotherswithmoreaccesstotheirowntrialdataandtocollaborateasappropriate.AsNeerajMohanofBlackstoneGroupsays,“Pharmacompaniesmaythinktheyneedtokeeptheirdatasecure,butnotbeingtransparentaboutclinicaltrialswillinfactputthemataperilousdisadvantageinfrontofpatientgroupsand,eventually,regulators.”
Reimaginepharmaplayersassolutionscompanies,notassetcompanies
Ashealthcarestart-upsandtechnologygiantsmoveintowhatwastraditionallythepharmaceuticaldomain,pharmacompanieswillneedtorevamptheirvaluepropositionssignificantly.Dr.Krishn